Active — Not RecruitingPhase 1

Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer

Switzerland14 participantsStarted 2020-09-11

Plain-language summary

Phase Ib clinical trial using Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP) in order to stimulate/induce both innate and adaptive immunity by activating T-cells and Natural Killer (NK) cells, combined with standard of care (SOC) adjuvant chemotherapy, followed by nivolumab, an antibody against Programmed Cell Death 1 (PD-1), to maintain and boost the vaccine's effect in patients with non-metastatic resectable pancreatic adenocarcinoma

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Agreement to follow instructions for methods of contraception for the couple from screening until 6 months after last vaccine dose, or last chemotherapy treatment, or last nivolumab treatment
✓. Women of childbearing potentia must have a negative urine pregnancy test within 7 days, before registration. A positive urine test must be confirmed by a serum pregnancy test.

What they're measuring

Number of cases for which vaccine is produced

Timeframe: 3 years after study activation

Assessment of adverse events

Timeframe: 3 years after study activation

Trial details

NCT IDNCT04627246

SponsorCentre Hospitalier Universitaire Vaudois

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-09

View on ClinicalTrials.gov More Pancreatic Adenocarcinoma trials